# A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)

> **NCT00172042** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 437 (actual)

## Conditions studied

- Non-Small-Cell Lung Cancer

## Interventions

- **DRUG:** Zoledronic acid 4 mg

## Key facts

- **NCT ID:** NCT00172042
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2010-05
- **Final completion:** 2010-06
- **Target enrollment:** 437 (ACTUAL)
- **Last updated:** 2015-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00172042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00172042, "A Study to Evaluate the Safety and Efficacy of Zoledronic Acid in the Prevention or Delaying of Bone Metastasis in Patients With Stage IIIA and IIIB Non-small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00172042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*